Quote: Namely, should we expect single-agent Vidaza to produce 7 CRs out of 9 patients in this patient population or is this HDAC truly adding a significant benefit here?
Dec 11 webcast goto 13:30 mark... "CR rate of 7% based on Vidaza literature"
Beyond actual CR rate is the question of durability. Although CR % is high, how durable are the CRs? That's important to know as they often aren't very durable in heme onc.
MEIP recently in-licensed a PI3K and I assume they intend to combine the PI3K with pracinostat. Note that CRIS is already well ahead of them in this regard with their dual PI3K/HDAC inhibitor CUDC-907.
Market Data 
Markets 
AI
